CRISPR Therapeutics offers a diversified gene-editing pipeline, with CASGEVY as its lead asset and multiple upcoming ...

Genomic studies of cancer patients have revealed thousands of mutations linked to tumor development, but researchers are unsure how the vast majority of these mutations contribute to cancer because ...

The CRISPR gene editing system holds tremendous promise. It has already revolutionized biomedical research by making gene editing a straightforward process. It involves using a guide RNA molecule that ...

Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77. Prime Medicine, a biotech whose wild ...

Update: On 8 December, the US Food and Drug Administration approved the CRISPR–Cas 9 therapy for sickle cell disease described in this story. Less than a month after the world’s first approval of a ...

CAR-T cells are highly effective in treating selected blood cancers. However, challenges remain with this new therapy, which was first approved in 2017 in the USA and a year later in Europe for ...

We recently compiled a list of the Top 11 CRISPR Stocks to Invest In. In this article, we are going to take a look at where Prime Medicine, Inc. (NASDAQ:PRME) stands against the other CRISPR stocks.

A woman born with almost no functional vision because of a genetic mutation has regained measurable sight after a single ...

A key FDA Advisory Committee met on Tuesday to discuss Vertex Pharmaceuticals’ groundbreaking IND application of exa-cel, a CRISPR-based therapy for sickle cell disease (SCD). Originally sponsored by ...

This story is republished from STAT, the health and medicine news site that’s a partner to the Globe. Sign up for STAT’s free Morning Rounds newsletter here. Prime Medicine, a Cambridge biotech whose ...